{"id":22174,"date":"2026-01-21T09:39:29","date_gmt":"2026-01-21T17:39:29","guid":{"rendered":"https:\/\/drugpolicy.ca\/les-problemes\/traitement-assiste-a-lheroine\/"},"modified":"2026-01-21T09:39:29","modified_gmt":"2026-01-21T17:39:29","slug":"traitement-assiste-a-lheroine","status":"publish","type":"page","link":"https:\/\/www.drugpolicy.ca\/fr\/les-problemes\/traitement-assiste-a-lheroine\/","title":{"rendered":"Traitement assist\u00e9 \u00e0 l&#8217;h\u00e9ro\u00efne"},"content":{"rendered":"\n<div class=\"wp-block-group alignwide is-layout-flow wp-block-group-is-layout-flow\"\/>\n<figure style=\"aspect-ratio:21\/9; margin-top:var(--wp--preset--spacing--50);margin-bottom:var(--wp--preset--spacing--60);\" class=\"alignwide wp-block-post-featured-image\"><img loading=\"lazy\" decoding=\"async\" width=\"2560\" height=\"1706\" src=\"https:\/\/www.drugpolicy.ca\/wp-content\/uploads\/2021\/11\/tim-cooper-FolqiosWgdM-unsplash-scaled.jpg\" class=\"attachment-post-thumbnail size-post-thumbnail wp-post-image\" alt=\"plantes de pavot\" style=\"width:100%;height:100%;object-fit:cover;\" srcset=\"https:\/\/www.drugpolicy.ca\/wp-content\/uploads\/2021\/11\/tim-cooper-FolqiosWgdM-unsplash-scaled.jpg 2560w, https:\/\/www.drugpolicy.ca\/wp-content\/uploads\/2021\/11\/tim-cooper-FolqiosWgdM-unsplash-300x200.jpg 300w, https:\/\/www.drugpolicy.ca\/wp-content\/uploads\/2021\/11\/tim-cooper-FolqiosWgdM-unsplash-1024x683.jpg 1024w, https:\/\/www.drugpolicy.ca\/wp-content\/uploads\/2021\/11\/tim-cooper-FolqiosWgdM-unsplash-768x512.jpg 768w, https:\/\/www.drugpolicy.ca\/wp-content\/uploads\/2021\/11\/tim-cooper-FolqiosWgdM-unsplash-1536x1024.jpg 1536w, https:\/\/www.drugpolicy.ca\/wp-content\/uploads\/2021\/11\/tim-cooper-FolqiosWgdM-unsplash-2048x1365.jpg 2048w\" sizes=\"auto, (max-width: 2560px) 100vw, 2560px\" \/><\/figure>\n<div class=\"wp-block-group has-global-padding is-layout-constrained wp-block-group-is-layout-constrained\" style=\"margin-top:var(--wp--preset--spacing--50);margin-bottom:var(--wp--preset--spacing--50)\">\n<p class=\"wp-block-paragraph\">Le traitement assist\u00e9 \u00e0 l&#8217;h\u00e9ro\u00efne (HAT) est une innovation qui engage les consommateurs d&#8217;h\u00e9ro\u00efne de longue dur\u00e9e dans un traitement qui comprend la fourniture d&#8217;h\u00e9ro\u00efne de qualit\u00e9 pharmaceutique (diac\u00e9tylmorphine) ainsi que d&#8217;autres interventions qui aident les individus \u00e0 obtenir de meilleurs r\u00e9sultats en mati\u00e8re de sant\u00e9.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Les programmes HAT ont \u00e9t\u00e9 lanc\u00e9s dans les ann\u00e9es 1990 en Suisse et constituent l&#8217;un des \u00e9l\u00e9ments de la r\u00e9ponse globale que les Suisses ont \u00e9labor\u00e9e face \u00e0 l&#8217;\u00e9pid\u00e9mie d\u00e9vastatrice de consommation de drogues injectables, de VIH et d&#8217;overdoses parmi les personnes qui consomment des drogues. Parall\u00e8lement \u00e0 des innovations telles que les programmes de m\u00e9thadone \u00e0 bas seuil, les sites d&#8217;injection supervis\u00e9s, les refuges pour les personnes vivant dans la rue et toute une s\u00e9rie de programmes m\u00e9dicaux et sanitaires, le traitement assist\u00e9 par l&#8217;h\u00e9ro\u00efne joue un r\u00f4le important dans l&#8217;engagement des consommateurs d&#8217;h\u00e9ro\u00efne de longue dur\u00e9e dans des programmes de traitement et d&#8217;autres programmes sociaux. Les r\u00e9sultats des programmes suisses de HAT ont \u00e9t\u00e9 positifs et l&#8217;approche a \u00e9t\u00e9 reproduite dans d&#8217;autres pays, notamment en Allemagne, aux Pays-Bas, en Espagne, au Danemark et au Canada.  <\/p>\n\n\n\n<p class=\"wp-block-paragraph\">L&#8217;exp\u00e9rience canadienne est similaire \u00e0 celle des programmes suisses, mais le Canada n&#8217;a pas encore vu la mise en \u0153uvre d&#8217;un programme HAT enti\u00e8rement financ\u00e9. Au Canada, l&#8217;essai clinique NAOMI (North American Opiate Medication Initiative) s&#8217;est d\u00e9roul\u00e9 \u00e0 Vancouver et \u00e0 Montr\u00e9al entre 2005 et 2008. Les r\u00e9sultats de l&#8217;essai NAOMI sont similaires \u00e0 ceux des programmes suisses, en ce sens que les participants au volet h\u00e9ro\u00efne de l&#8217;essai ont obtenu des r\u00e9sultats positifs significatifs :  <\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Taux de r\u00e9tention \u00e9lev\u00e9 dans le programme de traitement<\/li>\n\n\n\n<li>La consommation d&#8217;h\u00e9ro\u00efne ill\u00e9gale a chut\u00e9 de 70 %.<\/li>\n\n\n\n<li>La proportion de participants impliqu\u00e9s dans des activit\u00e9s ill\u00e9gales a diminu\u00e9 de moiti\u00e9, passant de plus de 70 % \u00e0 36 %.<\/li>\n\n\n\n<li>L&#8217;activit\u00e9 ill\u00e9gale parmi les participants a diminu\u00e9 de mani\u00e8re significative, tout comme la somme d&#8217;argent d\u00e9pens\u00e9e chaque mois pour les drogues ill\u00e9gales.<\/li>\n\n\n\n<li>Des am\u00e9liorations notables de l&#8217;\u00e9tat de sant\u00e9 des participants ont \u00e9galement \u00e9t\u00e9 constat\u00e9es.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">L&#8217;essai NAOMI a pris fin en 2008 et le nouveau gouvernement conservateur (\u00e9lu en 2005) n&#8217;\u00e9tait pas favorable \u00e0 la poursuite de l&#8217;exp\u00e9rience HAT en tant que programme de traitement. Sant\u00e9 Canada n&#8217;a pas autoris\u00e9 la poursuite du traitement des patients qui avaient obtenu de bons r\u00e9sultats dans le cadre de l&#8217;essai NAOMI et les participants ont d\u00fb choisir entre retourner \u00e0 la m\u00e9thadone ou suivre un programme de traitement fond\u00e9 sur l&#8217;abstinence. <\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Un nouveau projet de recherche a \u00e9t\u00e9 d\u00e9velopp\u00e9, The Study to Assess Longer-term Opioid Medication Effectiveness (SALOME), qui a commenc\u00e9 \u00e0 recruter des participants en 2011 dans le but de comparer la diac\u00e9tylmorphine, le principe actif de l&#8217;h\u00e9ro\u00efne, et l&#8217;hydromorphone (HDM), un analg\u00e9sique l\u00e9gal et autoris\u00e9. Cette recherche est actuellement en cours. <\/p>\n\n\n\n<p class=\"wp-block-paragraph\">En mai 2015, la Cour supr\u00eame de la Colombie-Britannique a statu\u00e9 que les patients qui avaient termin\u00e9 le protocole de traitement d&#8217;un an et qui b\u00e9n\u00e9ficiaient de l&#8217;h\u00e9ro\u00efne pouvaient continuer \u00e0 recevoir le traitement en dehors du cadre de la recherche. Cette d\u00e9cision est le r\u00e9sultat d&#8217;une contestation constitutionnelle de la r\u00e9glementation f\u00e9d\u00e9rale qui emp\u00eache les m\u00e9decins de prescrire une th\u00e9rapie assist\u00e9e par l&#8217;h\u00e9ro\u00efne \u00e0 leurs patients. Providence Health Care et la Pivot Legal Society, qui repr\u00e9sente cinq des participants \u00e0 l&#8217;\u00e9tude Salome, ont lanc\u00e9 ce recours.  <\/p>\n\n\n\n<p class=\"wp-block-paragraph\">En fait, le traitement assist\u00e9 \u00e0 l&#8217;h\u00e9ro\u00efne est en cours \u00e0 Vancouver, mais sa situation est pr\u00e9caire en raison d&#8217;une contestation judiciaire en cours. Des programmes de traitement de l&#8217;h\u00e9ro\u00efne existent en Suisse, en Allemagne, aux Pays-Bas, au Danemark, en Espagne et au Royaume-Uni. En 2012, l&#8217;Union europ\u00e9enne et la Suisse comptaient environ 2 400 personnes b\u00e9n\u00e9ficiant d&#8217;un traitement assist\u00e9 \u00e0 l&#8217;h\u00e9ro\u00efne. Ce traitement a \u00e9t\u00e9 int\u00e9gr\u00e9 \u00e0 l&#8217;\u00e9ventail des options th\u00e9rapeutiques disponibles pour les consommateurs d&#8217;h\u00e9ro\u00efne qui n&#8217;ont pas obtenu de r\u00e9sultats satisfaisants avec les autres modalit\u00e9s de traitement qui leur sont propos\u00e9es.  <\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Compte tenu de l&#8217;abondance des preuves qui ont \u00e9merg\u00e9 au cours des 20 derni\u00e8res ann\u00e9es, la Coalition canadienne des politiques sur des drogues soutient fermement la mise en \u0153uvre de programmes de traitement assist\u00e9 par l&#8217;h\u00e9ro\u00efne l\u00e0 o\u00f9 ils sont n\u00e9cessaires au Canada.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Pour en savoir plus<\/strong><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Pour une vue d&#8217;ensemble des traitements assist\u00e9s \u00e0 l&#8217;h\u00e9ro\u00efne en Europe, voir la publication de l&#8217;Observatoire europ\u00e9en des drogues et des toxicomanies, <a href=\"http:\/\/www.emcdda.europa.eu\/publications\/insights\/heroin-assisted-treatment\" target=\"_blank\" rel=\"noreferrer noopener\">New Heroin-Assisted Treatment<\/a>, 2012.<\/li>\n\n\n\n<li>Pour plus d&#8217;informations sur la contestation constitutionnelle, consultez le <a href=\"http:\/\/www.pivotlegal.org\/the_hat_injunction_what_does_it_mean\" target=\"_blank\" rel=\"noreferrer noopener\">blog de<\/a> la Pivot Legal Society sur l&#8217;action HAT : Qu&#8217;est-ce que cela signifie ?<\/li>\n\n\n\n<li><a href=\"http:\/\/www.providencehealthcare.org\/salome\/faqs.html\" target=\"_blank\" rel=\"noreferrer noopener\">\u00c9tude visant \u00e0 \u00e9valuer l&#8217;efficacit\u00e9 \u00e0 long terme des m\u00e9dicaments opio\u00efdes<\/a> (SALOME)<\/li>\n\n\n\n<li><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC2587648\/\" target=\"_blank\" rel=\"noreferrer noopener\">Initiative nord-am\u00e9ricaine sur les m\u00e9dicaments opiac\u00e9s<\/a><\/li>\n<\/ul>\n<\/div>\n\n<div style=\"height:var(--wp--preset--spacing--60)\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Le traitement assist\u00e9 \u00e0 l&#8217;h\u00e9ro\u00efne (HAT) est une innovation qui engage les consommateurs d&#8217;h\u00e9ro\u00efne de longue dur\u00e9e dans un traitement qui comprend la fourniture d&#8217;h\u00e9ro\u00efne de qualit\u00e9 pharmaceutique (diac\u00e9tylmorphine) ainsi que d&#8217;autres interventions qui aident les individus \u00e0 obtenir de meilleurs r\u00e9sultats en mati\u00e8re de sant\u00e9. Les programmes HAT ont \u00e9t\u00e9 lanc\u00e9s dans les ann\u00e9es [&hellip;]<\/p>\n","protected":false},"author":53,"featured_media":17216,"parent":22088,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"_crdt_document":"","footnotes":""},"class_list":["post-22174","page","type-page","status-publish","has-post-thumbnail","hentry"],"acf":[],"mb":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Traitement assist\u00e9 \u00e0 l&#039;h\u00e9ro\u00efne - Canadian Drug Policy Coalition<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.drugpolicy.ca\/fr\/les-problemes\/traitement-assiste-a-lheroine\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Traitement assist\u00e9 \u00e0 l&#039;h\u00e9ro\u00efne - Canadian Drug Policy Coalition\" \/>\n<meta property=\"og:description\" content=\"Le traitement assist\u00e9 \u00e0 l&#8217;h\u00e9ro\u00efne (HAT) est une innovation qui engage les consommateurs d&#8217;h\u00e9ro\u00efne de longue dur\u00e9e dans un traitement qui comprend la fourniture d&#8217;h\u00e9ro\u00efne de qualit\u00e9 pharmaceutique (diac\u00e9tylmorphine) ainsi que d&#8217;autres interventions qui aident les individus \u00e0 obtenir de meilleurs r\u00e9sultats en mati\u00e8re de sant\u00e9. Les programmes HAT ont \u00e9t\u00e9 lanc\u00e9s dans les ann\u00e9es [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.drugpolicy.ca\/fr\/les-problemes\/traitement-assiste-a-lheroine\/\" \/>\n<meta property=\"og:site_name\" content=\"Canadian Drug Policy Coalition\" \/>\n<meta property=\"og:image\" content=\"https:\/\/drugpolicy.ca\/wp-content\/uploads\/2021\/11\/tim-cooper-FolqiosWgdM-unsplash-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1706\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data1\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.drugpolicy.ca\\\/fr\\\/les-problemes\\\/traitement-assiste-a-lheroine\\\/\",\"url\":\"https:\\\/\\\/www.drugpolicy.ca\\\/fr\\\/les-problemes\\\/traitement-assiste-a-lheroine\\\/\",\"name\":\"Traitement assist\u00e9 \u00e0 l'h\u00e9ro\u00efne - Canadian Drug Policy Coalition\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/mail.canadiandrugpolicy.ca\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.drugpolicy.ca\\\/fr\\\/les-problemes\\\/traitement-assiste-a-lheroine\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.drugpolicy.ca\\\/fr\\\/les-problemes\\\/traitement-assiste-a-lheroine\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.drugpolicy.ca\\\/wp-content\\\/uploads\\\/2021\\\/11\\\/tim-cooper-FolqiosWgdM-unsplash-scaled.jpg\",\"datePublished\":\"2026-01-21T17:39:29+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.drugpolicy.ca\\\/fr\\\/les-problemes\\\/traitement-assiste-a-lheroine\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.drugpolicy.ca\\\/fr\\\/les-problemes\\\/traitement-assiste-a-lheroine\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.drugpolicy.ca\\\/fr\\\/les-problemes\\\/traitement-assiste-a-lheroine\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.drugpolicy.ca\\\/wp-content\\\/uploads\\\/2021\\\/11\\\/tim-cooper-FolqiosWgdM-unsplash-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/www.drugpolicy.ca\\\/wp-content\\\/uploads\\\/2021\\\/11\\\/tim-cooper-FolqiosWgdM-unsplash-scaled.jpg\",\"width\":2560,\"height\":1706,\"caption\":\"(Unsplash)\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.drugpolicy.ca\\\/fr\\\/les-problemes\\\/traitement-assiste-a-lheroine\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.drugpolicy.ca\\\/fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Les probl\u00e8mes\",\"item\":\"https:\\\/\\\/drugpolicy.ca\\\/fr\\\/les-problemes\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Traitement assist\u00e9 \u00e0 l&#8217;h\u00e9ro\u00efne\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/mail.canadiandrugpolicy.ca\\\/#website\",\"url\":\"https:\\\/\\\/mail.canadiandrugpolicy.ca\\\/\",\"name\":\"Canadian Drug Policy Coalition\",\"description\":\"Change policy. Save lives.\",\"publisher\":{\"@id\":\"https:\\\/\\\/mail.canadiandrugpolicy.ca\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/mail.canadiandrugpolicy.ca\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/mail.canadiandrugpolicy.ca\\\/#organization\",\"name\":\"Canadian Drug Policy Coalition\",\"url\":\"https:\\\/\\\/mail.canadiandrugpolicy.ca\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/mail.canadiandrugpolicy.ca\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/drugpolicy.ca\\\/wp-content\\\/uploads\\\/2019\\\/04\\\/CDPC-logo-white-on-red-150-dpi.jpg\",\"contentUrl\":\"https:\\\/\\\/drugpolicy.ca\\\/wp-content\\\/uploads\\\/2019\\\/04\\\/CDPC-logo-white-on-red-150-dpi.jpg\",\"width\":332,\"height\":333,\"caption\":\"Canadian Drug Policy Coalition\"},\"image\":{\"@id\":\"https:\\\/\\\/mail.canadiandrugpolicy.ca\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Traitement assist\u00e9 \u00e0 l'h\u00e9ro\u00efne - Canadian Drug Policy Coalition","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.drugpolicy.ca\/fr\/les-problemes\/traitement-assiste-a-lheroine\/","og_locale":"fr_FR","og_type":"article","og_title":"Traitement assist\u00e9 \u00e0 l'h\u00e9ro\u00efne - Canadian Drug Policy Coalition","og_description":"Le traitement assist\u00e9 \u00e0 l&#8217;h\u00e9ro\u00efne (HAT) est une innovation qui engage les consommateurs d&#8217;h\u00e9ro\u00efne de longue dur\u00e9e dans un traitement qui comprend la fourniture d&#8217;h\u00e9ro\u00efne de qualit\u00e9 pharmaceutique (diac\u00e9tylmorphine) ainsi que d&#8217;autres interventions qui aident les individus \u00e0 obtenir de meilleurs r\u00e9sultats en mati\u00e8re de sant\u00e9. Les programmes HAT ont \u00e9t\u00e9 lanc\u00e9s dans les ann\u00e9es [&hellip;]","og_url":"https:\/\/www.drugpolicy.ca\/fr\/les-problemes\/traitement-assiste-a-lheroine\/","og_site_name":"Canadian Drug Policy Coalition","og_image":[{"width":2560,"height":1706,"url":"https:\/\/drugpolicy.ca\/wp-content\/uploads\/2021\/11\/tim-cooper-FolqiosWgdM-unsplash-scaled.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_misc":{"Dur\u00e9e de lecture estim\u00e9e":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.drugpolicy.ca\/fr\/les-problemes\/traitement-assiste-a-lheroine\/","url":"https:\/\/www.drugpolicy.ca\/fr\/les-problemes\/traitement-assiste-a-lheroine\/","name":"Traitement assist\u00e9 \u00e0 l'h\u00e9ro\u00efne - Canadian Drug Policy Coalition","isPartOf":{"@id":"https:\/\/mail.canadiandrugpolicy.ca\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.drugpolicy.ca\/fr\/les-problemes\/traitement-assiste-a-lheroine\/#primaryimage"},"image":{"@id":"https:\/\/www.drugpolicy.ca\/fr\/les-problemes\/traitement-assiste-a-lheroine\/#primaryimage"},"thumbnailUrl":"https:\/\/www.drugpolicy.ca\/wp-content\/uploads\/2021\/11\/tim-cooper-FolqiosWgdM-unsplash-scaled.jpg","datePublished":"2026-01-21T17:39:29+00:00","breadcrumb":{"@id":"https:\/\/www.drugpolicy.ca\/fr\/les-problemes\/traitement-assiste-a-lheroine\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.drugpolicy.ca\/fr\/les-problemes\/traitement-assiste-a-lheroine\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.drugpolicy.ca\/fr\/les-problemes\/traitement-assiste-a-lheroine\/#primaryimage","url":"https:\/\/www.drugpolicy.ca\/wp-content\/uploads\/2021\/11\/tim-cooper-FolqiosWgdM-unsplash-scaled.jpg","contentUrl":"https:\/\/www.drugpolicy.ca\/wp-content\/uploads\/2021\/11\/tim-cooper-FolqiosWgdM-unsplash-scaled.jpg","width":2560,"height":1706,"caption":"(Unsplash)"},{"@type":"BreadcrumbList","@id":"https:\/\/www.drugpolicy.ca\/fr\/les-problemes\/traitement-assiste-a-lheroine\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.drugpolicy.ca\/fr\/"},{"@type":"ListItem","position":2,"name":"Les probl\u00e8mes","item":"https:\/\/drugpolicy.ca\/fr\/les-problemes\/"},{"@type":"ListItem","position":3,"name":"Traitement assist\u00e9 \u00e0 l&#8217;h\u00e9ro\u00efne"}]},{"@type":"WebSite","@id":"https:\/\/mail.canadiandrugpolicy.ca\/#website","url":"https:\/\/mail.canadiandrugpolicy.ca\/","name":"Canadian Drug Policy Coalition","description":"Change policy. Save lives.","publisher":{"@id":"https:\/\/mail.canadiandrugpolicy.ca\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/mail.canadiandrugpolicy.ca\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/mail.canadiandrugpolicy.ca\/#organization","name":"Canadian Drug Policy Coalition","url":"https:\/\/mail.canadiandrugpolicy.ca\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/mail.canadiandrugpolicy.ca\/#\/schema\/logo\/image\/","url":"https:\/\/drugpolicy.ca\/wp-content\/uploads\/2019\/04\/CDPC-logo-white-on-red-150-dpi.jpg","contentUrl":"https:\/\/drugpolicy.ca\/wp-content\/uploads\/2019\/04\/CDPC-logo-white-on-red-150-dpi.jpg","width":332,"height":333,"caption":"Canadian Drug Policy Coalition"},"image":{"@id":"https:\/\/mail.canadiandrugpolicy.ca\/#\/schema\/logo\/image\/"}}]}},"mfb_rest_fields":["title","yoast_head","yoast_head_json"],"_links":{"self":[{"href":"https:\/\/www.drugpolicy.ca\/fr\/wp-json\/wp\/v2\/pages\/22174","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.drugpolicy.ca\/fr\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.drugpolicy.ca\/fr\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.drugpolicy.ca\/fr\/wp-json\/wp\/v2\/users\/53"}],"replies":[{"embeddable":true,"href":"https:\/\/www.drugpolicy.ca\/fr\/wp-json\/wp\/v2\/comments?post=22174"}],"version-history":[{"count":1,"href":"https:\/\/www.drugpolicy.ca\/fr\/wp-json\/wp\/v2\/pages\/22174\/revisions"}],"predecessor-version":[{"id":22175,"href":"https:\/\/www.drugpolicy.ca\/fr\/wp-json\/wp\/v2\/pages\/22174\/revisions\/22175"}],"up":[{"embeddable":true,"href":"https:\/\/www.drugpolicy.ca\/fr\/wp-json\/wp\/v2\/pages\/22088"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.drugpolicy.ca\/fr\/wp-json\/wp\/v2\/media\/17216"}],"wp:attachment":[{"href":"https:\/\/www.drugpolicy.ca\/fr\/wp-json\/wp\/v2\/media?parent=22174"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}